Market Need
The global market for wound care in 2021 exceeds USD$16 billion , of which 2/3 are Advanced Wound Care products (growing rapidly due to causes such as diabetes epidemics). A significant and fastest growing part of the market is in developing nations in Asia, Africa and South America.
Diabetic foot ulcers are one of the most common and serious complications associated with diabetes mellitus and affect around 15% of patients with diabetes in their lifetime. A failure to heal can often lead to amputation. The diabetic condition impacts negatively on normal wound healing by affecting the microvasculature so that the wound is poorly vascularised. It also adversely affects normal innervation leading to the loss of peripheral sensory and autonomic nerves and the constant high glucose has an adverse effect on the immune system making the patient less able to counteract skin infections.
Technology
Cannenta has acquired exclusive rights to a patented unique sugar-based angiogenesis factor for accelerating wound recovery in patients.
The technology works by stimulating the patient production of vascular endothelial growth factor (VEGF) which is a protein that stimulates the formation of blood vessels, which in turn is the prerequisite to forming a viable wound bed for new skin formation.
The angiogenesis factor can be incorporated into a range of conventional wound dressings for convenient application to the patient.
Cannenta Business
Cannenta is currently in clinical trials in Australia with lead hydrogel based product intended for initial registration. The product range will be extended over time to cover additional indications for a variety of chronic or difficult to heal wounds.
The company works with healthcare providers and established distributors in the target markets.
Key People
Iain Ralph
David Zou
Xenia Sango
Dr Muhammad Yar
Prof Sheila MacNeil
Winthrop Prof Fiona Wood (AM)
Dr P. Stuart Esnouf
